Landmark bill grants Uber and Lyft drivers collective bargaining rights, signaling a potential shift in the gig work model.
First-of-its-kind maintenance therapy approved for extensive-stage small cell lung cancer, a historically difficult-to-treat malignancy.
The designation for ALTO-101 targets cognitive impairment, a debilitating aspect of schizophrenia with no currently approved treatments.
Investor demand drives prices to new all-time highs as Bitcoin balances on exchanges plummet to a six-year low.
Fiscal paralysis in Washington delays key economic data while the central bank cuts rates to support a cooling economy, creating a complex outlook for investors.
The U.S. Food and Drug Administration has accepted for review the company's New Drug Application for Relacorilant, a treatment for Cushing's syndrome.
Key approvals for Regeneron, Corcept, and a Fast Track designation for Alto Neuroscience signal a positive regulatory environment.
Key approvals and fast-track designations for Insmed, Alto Neuroscience, and Corcept Therapeutics boost investor confidence in the industry's regulatory landscape.